384337-90-0

Basic information

• Product Name: methyl(1-phenylmethyl-4-methylpiperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine
• Synonyms: methyl(1-phenylmethyl-4-methylpiperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine
• CAS NO: 384337-90-0
• Molecular Weight: 335.452
• Mol File: 384337-90-0.mol
• Article Data: 7

Chemical Properties

• Density: 1.205±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl(1-phenylmethyl-4-methylpiperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: methyl(1-phenylmethyl-4-methylpiperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine(384337-90-0)
• EPA Substance Registry System: methyl(1-phenylmethyl-4-methylpiperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine(384337-90-0)

Safety Data

• Hazardous Substances Data: 384337-90-0(Hazardous Substances Data)

Upstream product

• 384338-23-2 (1-benzyl-4-methyl-piperidin-3-yl)-methyl-amine 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 1228879-37-5 N,4-dimethyl-1-(phenylmethyl)-3-piperidineamine bishydrochloride 
• 1252883-87-6 N-(1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1354621-59-2 cis-N-benzyl-3-methoxycarbonylamino-4-methylpiperidine 

Downstream Products

• 1252883-90-1 N-((3S,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d] pyrimidin-4-amine 
• 1259404-17-5 tasocitinib 
• 540737-29-9 Tofacitinib citrate 
• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 
• 384336-73-6 (3R,4R)-methyl-(4-methyl-piperidin-3-yl)-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amine 

Relevant articles and documents

EFFICIENT METHOD FOR THE PREPARATION OF TOFACITINIB CITRATE

Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises: 1. Condensation between intermediates VII and VIII to give intermediate VI 2. Hydrogenation of intermediate VI to give intermediate V 3. Resolution of intermediate V to give intermediate IV with enantiomeric purity >99% 4. Release of intermediate IV in a basic medium to give intermediate III 5. N-acylation reaction of intermediate III to give II (tofacitinib) 6. Salification of intermediate II to give tofacitinib monocitrate (I)

PIPERIDINE INHIBITORS OF JANUS KINASE 3

The present invention relates to a new piperidine inhibitors of Janus Kinase 3 activity, pharmaceutical compositions thereof, and methods of use there-of.

Method of treatment of atherosclerosis

A method of treating or preventing atherosclerosis comprising administering a compound of the formula wherein R1, R2 and R3 are as defined above.